Aim: In metastatic prostate cancer patients PSMA targeting radioligands have gained significant impact as theranostic probes. In this study a correlation between total tumor volume (TTV) and measured kidney dose as well as salivary glands (SG) uptake in 177Lu-PSMA-617 therapy was evaluated.Methods: Eleven consecutive prostate cancer patients receiving a first cylcle of 177Lu-PSMA-617 (administered activity of approximately 6GBq) were included. The 68Ga-PSMA-11 PET/CT scan previous to therapy was used to determine TTV and SG uptake (glandulae submandibularis) employing PMOD version 3.403 with different 68Ga-PSMA-11 thresholds based on the standardized uptake value (SUV).The kidney dose was estimated with the software ULMDOS using planar whol...
Purpose: [177Lu]Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel treatment for metastatic cas...
Background: 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([68Ga]PSMA-11) has been increasingly used to...
Introduction Patient eligibility for [177Lu]Lu-PSMA therapy remains a challenge, with only 40-60% re...
Aim: In metastatic prostate cancer patients PSMA targeting radioligands have gained significant impa...
Background: [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and salivary gland...
We aimed to systematically determine the impact of tumor burden on 68Ga-prostate-specific membrane a...
INTRODUCTION: While [(177)Lu]Lu-PSMA radioligand therapy is currently only applied in end-stage meta...
AimWe investigated the whole-body distribution and the radiation dosimetry of [F-18]-JK-PSMA-7, a no...
Aim We investigated the whole-body distribution and the radiation dosimetry of [18F]-JK-PSMA-7, a no...
Radionuclide therapy using the small molecule PSMA bound to the beta-emitting radionuclide, Lutetium...
Purpose: Various radiolabeled prostate-specific membrane antigen (PSMA)–targeting tracers are clinic...
Prostate-specific membrane antigen (PSMA) is a well-established target for nuclear imaging and thera...
In molecular radiotherapy with 177Lu-labeled prostate specific membrane antigen (PSMA) peptides, kid...
Introduction PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treat...
We report the dosimetric evaluation of prostate-specific membrane antigen-based radioligand therapy ...
Purpose: [177Lu]Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel treatment for metastatic cas...
Background: 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([68Ga]PSMA-11) has been increasingly used to...
Introduction Patient eligibility for [177Lu]Lu-PSMA therapy remains a challenge, with only 40-60% re...
Aim: In metastatic prostate cancer patients PSMA targeting radioligands have gained significant impa...
Background: [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and salivary gland...
We aimed to systematically determine the impact of tumor burden on 68Ga-prostate-specific membrane a...
INTRODUCTION: While [(177)Lu]Lu-PSMA radioligand therapy is currently only applied in end-stage meta...
AimWe investigated the whole-body distribution and the radiation dosimetry of [F-18]-JK-PSMA-7, a no...
Aim We investigated the whole-body distribution and the radiation dosimetry of [18F]-JK-PSMA-7, a no...
Radionuclide therapy using the small molecule PSMA bound to the beta-emitting radionuclide, Lutetium...
Purpose: Various radiolabeled prostate-specific membrane antigen (PSMA)–targeting tracers are clinic...
Prostate-specific membrane antigen (PSMA) is a well-established target for nuclear imaging and thera...
In molecular radiotherapy with 177Lu-labeled prostate specific membrane antigen (PSMA) peptides, kid...
Introduction PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treat...
We report the dosimetric evaluation of prostate-specific membrane antigen-based radioligand therapy ...
Purpose: [177Lu]Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel treatment for metastatic cas...
Background: 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([68Ga]PSMA-11) has been increasingly used to...
Introduction Patient eligibility for [177Lu]Lu-PSMA therapy remains a challenge, with only 40-60% re...